Full-year results are out and most publicly traded clinical labs have filed their 10-Ks, signaling that it’s time for LIR’s periodic benchmarking analysis. Based on earnings from the full-year 2008, hematopathology specialty lab Genoptix (San Diego) continues to lead in productivity—for both revenue per full-time employee (FTE) and pretax income per FTE (see Table 1).

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

April 2009 - Table of Contents

LIR April 2009 (full PDF issue)

Economic Stimulus Bill’s $19 Billion in IT Investments Include Incentives for Pathologists, but Not Labs

California AG Alleges Billing Fraud in Suit Against Quest, LabCorp, and Five Other Labs

Survey Finds 63% of Labs Grappling With High Vacancy Rates; Medical Technologist Rate Highest at Over 10%

Genoptix Leads in FY2008 Productivity Benchmark Measures

Inside the Lab Industry: Stimulus Bill’s $19 Billion in IT Investment Provides Incentives, Penalties for Lab Industry

Cleveland Clinic Eyes $25 Million Reference Lab Expansion, Broadens Focus on Cardiac Esoteric Testing

Genoptix FY08 Revenues Up 96% to $116 Million; Growth Includes Move Into Solid Tumor Testing

Enzo Biochem Names New Clinical Lab President; Acquires Assay Designs

Lab Stocks Down 16% So Far in March; Down 7% So Far in 2009

LabCorp, Quest Name New Chief Medical Officers